Cargando…
THU389 Euglycemic Diabetic Ketoacidosis With Prolonged Ketosis Due To SGLT-2 Inhibitor
Disclosure: N. Viera Feliciano: None. J. Johannan: None. E. Nosova: None. C.J. Levy: Advisory Board Member; Self; Eli Lilly & Company, Dexcom. Research Investigator; Self; NIH, Helmsley Foundation, Abbott, Dexcom, Insulet, Tandem. Background: Euglycemic Diabetic ketoacidosis is a known complicat...
Autores principales: | Viera Feliciano, Natalia, Johannan, Jiby, Nosova, Emily, Joan Levy, Carol |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554856/ http://dx.doi.org/10.1210/jendso/bvad114.822 |
Ejemplares similares
-
THU387 Euglycemic Diabetic Ketoacidosis And SGLT-2 Inhibitor Use
por: Abrahimi, Nora, et al.
Publicado: (2023) -
THU359 A Classical Case Of SGLT-2 Inhibitor Euglycemic Ketoacidosis In A Patient With Glucotoxicity
por: Amankwah, Samuel, et al.
Publicado: (2023) -
Euglycemic Diabetic Ketoacidosis With SGLT-2 Inhibitor
por: Manas, F N U, et al.
Publicado: (2021) -
THU324 Euglycemic Diabetic Ketoacidosis Coinciding With COVID-19 Infection During Pregnancy
por: Alkhathlan, Mujahed, et al.
Publicado: (2023) -
PSUN190 Is Euglycemic Diabetic Ketoacidosis an Underrecognized Risk of SGLT2 Inhibitor Utilization?
por: Block, Romy, et al.
Publicado: (2022)